[L-dopa therapy of parkinson syndrome].
D001545:Benserazide / Q000009:adverse effects / Q000627:therapeutic use; D001711:Biotransformation; D002230:Carbidopa / Q000009:adverse effects / Q000627:therapeutic use; D003342:Corpus Striatum / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D008134:Long-Term Care; D010300:Parkinson Disease / Q000188:drug therapy*; D011954:Receptors, Dopamine / Q000187:drug effects
D011954:Receptors, Dopamine; D007980:Levodopa; D001545:Benserazide; D002230:Carbidopa; D004298:Dopamine
L-Dopa Therapie des Parkinsonsyndroms.